EcoDrugPlus

Proteasome Subunit Beta 11

Ensembl ID : ENSHBUG00000003403
Gene Symbol: PSMB11
1 Cross references
169 Possible Orthologues:

Proteasome Subunit Beta Type-11-Like

Ensembl ID : ENSHBUG00000023481
Gene Symbol: LOC102307191
3 Cross references
159 Possible Orthologues:

Proteasome Subunit Beta Type-5-Like

Ensembl ID : ENSHBUG00000003438
Gene Symbol: LOC102305606
3 Cross references
203 Possible Orthologues:

Proteasome Subunit Beta Type-7-Like

Ensembl ID : ENSHBUG00000007566
Gene Symbol: LOC102289461
3 Cross references
171 Possible Orthologues:

Proteasome Subunit Beta Type-7-Like

Ensembl ID : ENSHBUG00000006441
Gene Symbol: LOC102296354
3 Cross references
216 Possible Orthologues:

Proteasome Subunit Beta Type-8-Like

Ensembl ID : ENSHBUG00000010761
Gene Symbol: LOC102299877
3 Cross references
215 Possible Orthologues:

Proteasome Subunit Beta Type-8-Like

Ensembl ID : ENSHBUG00000004694
Gene Symbol: LOC102313461
3 Cross references
215 Possible Orthologues:

Proteasome Subunit Beta Type-9

Ensembl ID : ENSHBUG00000000871
Gene Symbol: LOC102300494
3 Cross references
199 Possible Orthologues:

Protein Arginine Methyltransferase 5

Ensembl ID : ENSHBUG00000003185
Gene Symbol: PRMT5
3 Cross references
198 Possible Orthologues:

Protein Farnesyltransferase Subunit Beta-Like

Ensembl ID : ENSHBUG00000017259
Gene Symbol: LOC102293025
3 Cross references
209 Possible Orthologues:

Protein Kinase C Alpha

Ensembl ID : ENSHBUG00000015189
Gene Symbol: PRKCA
3 Cross references
213 Possible Orthologues:

Protein Kinase C Beta

Ensembl ID : ENSHBUG00000016360
Gene Symbol: PRKCB
4 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).